Practicability of combined treatment with calcipotriol/betamethasone gel (Daivobet® Gel) and improvement of quality of life in patients with psoriasis

Authors


  • Conflicts of interest This study was supported by LEO Pharma GmbH. Dr. Christoph Eicke was commissioned by LEO Pharma GmbH with the management of the study under the leadership of Dr. Holger Schilling (Medical Director). Data management and statistics were performed by Anfomed GmbH, Möhrendorf (Germany). Prof. Dr. Michael Sticherling has received honoraria as advisor and lecturer and travel expenses from LEO Pharma GmbH.

Correspondence to

Prof. Dr. Michael Sticherling

Department of Dermatology

University of Erlangen

Ulmenweg 18

91054 Erlangen, Germany

E-mail: michael.sticherling@uk-erlangen.de

Summary

Background

The successful treatment of psoriasis depends not only on the efficacy of the medication but also on patientsí acceptance and adherence to the prescribed regimen.

Patients and Methods

In this non-interventional, prospective trial 579 patients with psoriasis were treated once daily with the fixed combination of calcipotriol 50 μg/g plus betamethasone 0.5 mg/g (Daivobet® Gel) for 4 weeks. Comparing the new medication to their previous treatment, patients assessed their quality of life by means of the Dermatology Life Quality Index (DLQI), reported their therapy- associated burden in daily life by the Psoriasis Disability Index (PDI) and assessed how easy the new medication was to employ. Disease severity was rated at the start and end of the study by physicians and patients using a Global Assessment (PGA from 0–5 points) and the Body Surface Area (BSA) assessed by the physicians.

Results

Quality of life improved from 8.7 to 3.2 points (p < 0.0001) parallel to a significant decrease of PGA by 39.6% (p < 0.0001) and BSA (72.5% of patients with BSA > 4% before vs. 37.3% after therapy). The application of the study medication was 30% less time-consuming and handling associated with significantly higher patient satisfaction. Efficacy and tolerability of Daivobet® Gel versus prior treatment were judged “very good” in 85.7% vs. 27.6% of patients.

Conclusions

The study substantiates a significant improvement of the quality of life during therapy with the fixed combination. Patients benefit from the convenience and time-saving as compared to their prior treatment. Thus, Daivobet® Gel can be recommended as an effective and well-tolerated treatment which may easily be integrated into daily life of patients with psoriasis.

Ancillary